-
1
المؤلفون: Khaled Messaoudi, Patrick Saulnier, Anne Clavreul, Jean-Pierre Benoit, Fabienne Danhier, Frédéric Lagarce
المساهمون: UCL - SSS/LDRI - Louvain Drug Research Institute, Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), Unité de Pharmacologie Cellulaire et Moléculaire [Brussels], Louvain Drug Research Institute [Bruxelles, Belgique] (LDRI), Université Catholique de Louvain = Catholic University of Louvain (UCL)-Université Catholique de Louvain = Catholic University of Louvain (UCL), Univ Angers, Okina
المصدر: European Journal of Nanomedicine, Vol. 7, no.2, p. 97-107 (2015)
European Journal of Nanomedicine
European Journal of Nanomedicine, 2015, 7 (2), pp.97-107. ⟨10.1515/ejnm-2014-0041⟩مصطلحات موضوعية: Small interfering RNA, medicine.medical_treatment, EGFR, Biomedical Engineering, Medicine (miscellaneous), Bioengineering, [SDV.CAN]Life Sciences [q-bio]/Cancer, temozolomide, Biology, [SDV.CAN] Life Sciences [q-bio]/Cancer, SiRNA, medicine, Temozolomide, Gene silencing, galectin-1, Epidermal growth factor receptor, Physical and Theoretical Chemistry, Experimental cancer treatment, neoplasms, glioblastoma, In vitro, Gliome, 3. Good health, Concomitant, siRNA, Galectin-1, Immunology, Cancer research, biology.protein, MGMT, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::945fac43b5a05d4d80c356aab895eae5Test
https://hdl.handle.net/2078.1/168545Test -
2
المساهمون: Unité de Pharmacologie Cellulaire et Moléculaire [Brussels], Louvain Drug Research Institute [Bruxelles, Belgique] (LDRI), Université Catholique de Louvain = Catholic University of Louvain (UCL)-Université Catholique de Louvain = Catholic University of Louvain (UCL), Université Catholique de Louvain = Catholic University of Louvain (UCL), Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)
المصدر: International Journal of Pharmaceutics
International Journal of Pharmaceutics, Elsevier, 2015, 481, pp.154-161. ⟨10.1016/j.ijpharm.2015.01.051⟩مصطلحات موضوعية: Small interfering RNA, Pathology, Galectin 1, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Pharmaceutical Science, Lipid nanocapsules, Drug Delivery Systems, 0302 clinical medicine, Galectin-1, Medicine, Epidermal growth factor receptor, RNA, Small Interfering, 0303 health sciences, biology, medicine.diagnostic_test, Brain Neoplasms, Lipids, Tumor Burden, 3. Good health, Dacarbazine, ErbB Receptors, 030220 oncology & carcinogenesis, Female, medicine.drug, medicine.medical_specialty, EGFR, Mice, Nude, Immunofluorescence, 03 medical and health sciences, Nanocapsules, In vivo, Cell Line, Tumor, Temozolomide, Animals, Humans, Gene Silencing, Antineoplastic Agents, Alkylating, 030304 developmental biology, Chitosan, Chemotherapy, business.industry, Radiation therapy, Drug Resistance, Neoplasm, siRNA, Cancer research, biology.protein, business, Glioblastoma
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdbc0c7b274d79cc35bf52bedb95647eTest
https://hal.archives-ouvertes.fr/hal-01392431Test -
3
المؤلفون: Frédéric Lagarce, Anne Clavreul, Khaled Messaoudi
المساهمون: Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Univ Angers, Okina
المصدر: Drug Discovery Today
Drug Discovery Today, Elsevier, 2015, 20 (7), pp.899-905. ⟨10.1016/j.drudis.2015.02.011⟩
Drug Discovery Today, 2015, 20 (7), pp.899-905. ⟨10.1016/j.drudis.2015.02.011⟩مصطلحات موضوعية: medicine.medical_treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, Drug resistance, Pharmacology, Structure-Activity Relationship, [SDV.CAN] Life Sciences [q-bio]/Cancer, Glioma, Drug Discovery, medicine, Biomarkers, Tumor, Temozolomide, PTEN, Animals, Humans, Genetic Predisposition to Disease, Epidermal growth factor receptor, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Antineoplastic Agents, Alkylating, Chemotherapy, biology, Molecular Structure, Brain Neoplasms, medicine.disease, 3. Good health, Radiation therapy, Dacarbazine, Phenotype, Drug Resistance, Neoplasm, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Drug Design, Cancer research, biology.protein, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Mdm2, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Glioblastoma, medicine.drug, Signal Transduction
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c4ffe4b5db0124708d774f31f19e4aTest
https://pubmed.ncbi.nlm.nih.gov/25744176Test